Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: A randomized controlled trial

Journal of the American Medical Directors Association

Volumn 15, Issue 8, 2014, Pages 607.e5-607.e12

  Chan, Tuen Ching ^a,b   Hung, Ivan Fan Ngai ^b   Chan, Kwok Hung ^b   Li, Clara Pui Yan ^b   Li, Patrick Tsz Wai ^b   Luk, James Ka Hay ^a   Chu, Leung Wing ^b   Chan, Felix Hon Wai ^a  

^a Fung Yiu King Hospital   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Immunogenicity; Influenza vaccination; Intradermal vaccination; Nursing home older adults; Randomized controlled trial; Safety

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; ECCHYMOSIS; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION; HONG KONG; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MYALGIA; NURSING HOME; NURSING HOME PATIENT; OPEN STUDY; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN INDURATION; SKIN REDNESS; VERY ELDERLY; IMMUNOLOGY; INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; VIROLOGY; AGING; COMORBIDITY; DISEASE SEVERITY; DRUG SAFETY; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MAJOR CLINICAL STUDY; NONHUMAN; NUTRITIONAL STATUS; VIRUS STRAIN;

AGED, 80 AND OVER; FEMALE; HONG KONG; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; NURSING HOMES; PATIENT SAFETY;

EID: 84905001043     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.05.002     Document Type: Article

References (71)

1. Fleming D.M., Elliot A.J. The impact of influenza on the health and health care utilization of elderly people. Vaccine 2005, 23:51-559.
2. Pitman R.J., Melegaro A., Gelb D., et al. Assessing the burden of influenza and other respiratory infections in England and Wales. Jinfect 2007, 54:530-538.
3. World Health Organization Influenza vaccines. WHO position paper. Wkly Epidemiol Rec 2005, 80:277-287.
4. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAm Med Assoc 2003, 289:179-186.
5. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Efficacy of trivalent seasonal influenza vaccination on mortality and hospitalization in Chinese nursing home older adults. JAm Med Dir Assoc 2013, 14:889-894.
6. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Effectiveness of influenza vaccination in institutionalized older adults: A systematic review. JAm Med Dir Assoc 2013, 15:226.e1-226.e6.
7. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: A one-year prospective cohort study. Vaccine 2011, 29:7773-7778.
8. Jefferson T., Rivetti D., Rivetti A., et al. Efficacy and effectiveness of influenza vaccines in elderly people: A systematic review. Lancet 2005, 366:1165-1174.
9. Simansen L., Taylor R.J., Viboud C., et al. Mortality benefits of influenza vaccination in elderly people: An ongoing controversy. Lancet Infect Dis 2007, 7:658-666.
10. Grubeck-Loebenstein B., Della Bella S., Iorio A.M., et al. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009, 21:201-209.
11. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006, 24:1159-1169.
12. Loebermann M.1, Voss U., Meyer S., et al. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PloS One 2013, 8:e70866.
13. Guy B. The perfect mix: Recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
14. O Hagan DT MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6:699-710.
15. Falsey A.R., Treanor J.J., Tornieporth N., et al. Randomized double-blind controlled phase 3 trial comparing the immunogenicity of high dose and standard-dose influenza vaccine in adults 65 years of age and older. JInfect Dis 2009, 200:172-180.
16. Palache A.M., Beyer W.E., Sprenger M.J., et al. Antibody response after influenza immunization with various vaccine doses: A double-blind placebo-controlled, multicenter, dose-response study in elderly nursing home residents and young volunteers. Vaccine 1993, 11:3-9.
17. Lambert P.H., Laurent P.E. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?. Vaccine 2008, 26:3197-3208.
18. McElhaney J.E., Dutz J.P. Better influenza vaccines for older people: What will it take?. JInfect Dis 2008, 198:632-634.
19. Nicolas J.F., Guy B. Intradermal epidermal and transcutaneous vaccination: From immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
20. Arnou R., Icardi G., De Decker M., et al. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
21. Arnou R., Eavis P., Ambrozaitis A., et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized controlled, phase III trial. Human Vaccines 2010, 6:346-354.
22. Hung I.F., To K.K., Lee C.K., et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010, 51:274-279.
23. Kenny R.T., Frech S.A., Muenz L.R., et al. Dose sparing with intradermal injection of influenza vaccine. NEngl J Med 2004, 351:2295-2301.
24. Leroux-Roels I., Vets E., Freese R., et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomized controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
25. Young F., Marra F. Asystematic review of intradermal influenza vaccines. Vaccine 2011, 29:8788-8801.
26. Baluch A., Humar A., Eurich D., et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplantation 2013, 13:1026-1033.
27. Chuaychoo B., Wongsurakiat P., Nana A., et al. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine 2010, 28:4045-4051.
28. Gelinck L.B.S., van den Bemt B.J.F., Marijt W.A.F., et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009, 27:2469-2474.
29. Morelon E., Pouteil Noble C., Daoud S., et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were nonresponders to conventional influenza vaccination. Vaccine 2010, 28:6885-6890.
30. Arnou R., Frank M., Hagel T., et al. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: A survey of general practitioners and the general public in France and Germany. Adv Ther 2011, 28:555-565.
31. Dhont P.A., Albert A., Brenders P., et al. Acceptability of Intanza intradermal influenza vaccine in Belgium during the 2010-2011 influenza season. Adv Ther 2012, 29:562-577.
32. Durando P., Alicino C., Alberti M., et al. Acceptance and Safety of the intradermal influenza vaccine among the elderly in Italy: An on-field national study. Adv Ther 2012, 29:312-326.
33. Eizenberg P., Booy R., Naser N., et al. Acceptance of Intanze intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011, 28:640-649.
34. Garibaldi R.A. Residential care and the elderly: The burden of infection. JHosp Infect 1999, 43:S9-S18.
35. Naylor C.D. Meta-analysis and the met-epidemiology of clinical research. BMJ 1997, 315:917-919.
36. Richards C.L. Infection control in long-term care facilities. JAm Med Dir Assoc 2007, 8:S18-S25.
37. Chan T.C., Shea Y.F., Luk J.K., et al. Development and validation of a prognostic index for 2-year mortality in Chinese older residents living in nursing home. Geriatr Gerontol Int 2011, 12:555-562.
38. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Is nursing home residence an independent risk factor of mortality in Chinese older adults?. JAm Geriatr Soc 2013, 61:1430-1432.
39. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Is nursing home residence an independent risk factor of recurrent hospitalization in older adults?. JAm Med Dir Assoc 2013, 14:706-707.
40. Quick R.E., Hoge C.W., Hamilton D.J., et al. Underutilization of pneumococcal vaccine in nursing home in Washington State: Report of a serotype-specific outbreak and a survey. Am J Med 1993, 94:149-152.
41. Nuorti J.P., Butler J.C., Crutcher J.M., et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. NEngl J Med 1998, 338:1861-1868.
42. Beran J., Ambrozaitis A., Laiskonis A., et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: A 3-year randomized controlled safety and immunogenicity trial. BMC Med 2009, 7:13.
43. Chan T.C., Luk J.K., Chu L.W., et al. Validation study of Charlson Comorbidity Index in predicting mortality in Chinese older adults. Geriatr Gerontol Int 2013, 14:452-457.
44. Abellan van Kan G., Rolland Y.M., Morley J.E., et al. Frailty: Toward a clinical definition. JAm Med Dir Assoc 2008, 9:71-72.
45. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: Evidence for a phenotype. JGerontol Med Sci 2001, 56:146-156.
46. Morley J.E., Vellas B., van Kan G.A., et al. Frailty consensus: A call to action. JAm Med Dir Assoc 2013, 14:392-397.
47. Rockwood K., Abeysundera J., Mitniski A. How should we grade frailty in nursing home patients?. JAm Med Dir Assoc 2007, 8:595-603.
48. Rockwood K., Song X.W., Macknight C., et al. Aglobal clinical measure of fitness and frailty in elderly people. CMAJ 2005, 173:489-495.
49. Chan T.C., Luk J.K., Chu L.W., et al. Association between body mass index and cause-specific mortality as well as hospitalization in frail Chinese older adults [published online ahead of print January 12, 2014]. Geriatr Gerontol Int 2014, 10.1111/ggi.12230.
50. Chan T.C., Yap D.Y., Shea Y.F., et al. Prevalence and associated comorbidities of moderate to severe chronic renal impairment in Chinese nursing home older adults. JAm Med Dir Assoc 2012, 13:630-633.
51. Chan T.C., Yap D.Y., Shea Y.F., et al. Chronic kidney disease and its association with mortality and hospitalization in Chinese nursing home older residents. JAm Med Dir Assoc 2012, 13:782-787.
52. Chan T.C., Yap D.Y., Hung I.F.N., et al. The efficacy of influenza vaccination is reduced in nursing home older adults with moderate to severe renal impairment. JAm Med Dir Assoc 2013, 14:133-136.
53. Chan K.H., To K.K., Hung I.F., et al. Differences in antibody responses of individuals with natural injection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol 2011, 18:867-873.
54. European Committee for Proprietary Medicinal Products guideline. Note for guidance on harmonization of requirements for influenza vaccines. EMEA March 1997;CPMP/BWP/214/96.
55. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
56. Campbell J.D., Chambers C.V., Brady R.C., et al. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: Randomized controlled trial. Hum Vaccine 2011, 7:81-88.
57. Hung I.F.N., Levin Y., To K.K.W., et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012, 30:6427-6435.
58. Schumi J., Wittes J.T. Through the looking glass: Understanding noninferiority. Trials 2011, 12:106.
59. Chi R.C., Rock M.T., Neuzil K.M. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010, 50:1331-1338.
60. Pearton M., Kang S.M., Song J.M., et al. Changes in human Langerhans cells following intradermal injection of influenza virus like particle vaccines. PLoS One 2010, 5:e12410.
61. Estcourt M.J., Letourneau S., McMichael A.J., et al. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 2005, 35:2532-2540.
62. Holland D., Booy R., De Looze F., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. JInfect Dis 2008, 198:650-658.
63. Fabrizi F., Dixit V., Magnini M., et al. Meta-analysis: Intradermal vs intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006, 24:497-506.
64. La Montagne J.R., Fauci A.S. Intradermal influenza vaccination: Can less be more?. NEngl J Med 2004, 351:2330-2332.
65. Chan T.C., Hung I.F.N., Luk J.K.H., et al. Factors associated with influenza vaccination in Chinese nursing home older adults. JAm Med Dir Assoc 2013, 14:772-774.
66. Chan T.C., Hung I.F.N., Luk J.K., et al. Functional status of older nursing home residents can affect the efficacy of influenza vaccination. JGerontol Med Sci 2013, 68:324-330.
67. Sagawa M., Kojimahara N., Otsuka N., et al. Immune response to influenza vaccine in the elderly: Association with nutritional and physical status. Geriatr Gerontol Int 2011, 11:63-68.
68. Hara M., Tanaka K., Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: Association with nutritional status. Vaccine 2005, 23:1457-1463.
69. Remarque E.J., Cools H.J., Boere T.J., et al. Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home. BMJ 1996, 312:1015.
70. Allsup S.J., Shenkin A., Gosney M.A., et al. Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial. JAm Geriatr Soc 2004, 52:20-24.
71. Whelan P.J., Walwyn R., Gaughran F., et al. Impact of the demand for "proxy assent" on recruitment to a randomized controlled trial of vaccination testing in care homes. JMed Ethics 2013, 39:36-40.